Skip to main content

and
  1. Article

    Open Access

    Differential responses to immune checkpoint inhibitor dictated by pre-existing differential immune profiles in squamous cell carcinomas caused by same initial oncogenic drivers

    While immune checkpoint inhibitors (ICI) were approved for head and neck squamous cell carcinomas (HNSCCs), the response rate remains relatively low. Mechanisms underlying ICI unresponsiveness versus sensitivi...

    Samantha M. Y. Chen, Vince Popolizio in Journal of Experimental & Clinical Cancer … (2022)